Leading CRAC Channel Platform Company Delivering Drug Candidates For Inflammatory Diseases
CRAC Channel Technology
Calcium release-activated calcium channels, or CRAC channels, are responsible for replenishing the calcium stores inside many cell types. Since calcium is an important regulator of multiple biological functions, CRAC channel activation controls several of these functions including inflammation, vascular permeability and cell death.
Auxora Pipeline
CalciMedica is advancing their lead product candidate AuxoraTM for the treatment of acute inflammatory conditions such as acute pancreatitis and COVID-19 pneumonia.
News
CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia
CARDEA-Plus is designed to evaluate dosing, safety and efficacy of Auxora in combination with both tocilizumab and corticosteroids LA JOLLA, Calif., January 20, 2022 – CalciMedica …
CalciMedica Strengthens Board of Directors with Appointment of Finance Veteran Allan L. Shaw
LA JOLLA, Calif., November 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC channel company, today announced the appointment of Allan L. Shaw to …